Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AAV-hTERT for Alzheimer's Disease
NCT04133454Phase 1Unknown
- Sponsor
- Libella Gene Therapeutics
- Start
- Oct 2019
- Primary completion
- Jan 2021
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AAV-hTERT in Alzheimer's disease (AD), sponsored by Libella Gene Therapeutics. Primary endpoint: Incidence of adverse events at 12 months. Status: unknown.
02
Drugs
AAV-hTERT
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04133454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04133454.